PCRX - Pacira BioSciences Non-GAAP EPS of $0.64 misses by $0.19 revenue of $158M beats by $2.92M; reaffirms FY22 guidance

Pacira BioSciences press release (NASDAQ:PCRX): Q1 Non-GAAP EPS of $0.64 misses by $0.19. Revenue of $158M (+32.8% Y/Y) beats by $2.92M. Adjusted EBITDA was $53.8 million, or $1.20 per share (basic) and $1.16 per share (diluted) in the first quarter of 2022, compared to $36.2 million, or $0.83 per share (basic) and $0.79 per share (diluted) in the first quarter of 2021. Pacira ended the first quarter of 2022 with cash, cash equivalents and short-term available-for-sale investments  of $452.2 million. Cash provided by operations was $30.8 million in the first quarter of 2022, compared to $12.1 million in the first quarter of 2021. The company is reiterating its full-year 2022 operating expense guidance as follows: Non-GAAP R&D expense of $75 million to $85 million; Non-GAAP SG&A expense of $220 million to $230 million; and Stock-based compensation of $40 million to $45 million.

For further details see:

Pacira BioSciences Non-GAAP EPS of $0.64 misses by $0.19, revenue of $158M beats by $2.92M; reaffirms FY22 guidance